Salla disease
(Redirected from Sialic acid storage disease)
Salla disease, also known as Sialic Acid Storage Disease, Finnish type, is a rare autosomal recessive lysosomal storage disorder characterized by the accumulation of free sialic acid in lysosomes. It is part of a group of disorders known as the lysosomal storage diseases. Salla disease primarily affects the nervous system, leading to physical and mental impairment. It was first identified in the Salla region of Finland, where it has the highest prevalence, but it has since been diagnosed in individuals worldwide.
Symptoms and Signs[edit | edit source]
The symptoms of Salla disease typically manifest in infancy or early childhood. They include:
- Hypotonia (reduced muscle tone)
- Developmental delay and later, intellectual disability
- Ataxia (impaired balance and coordination)
- Nystagmus (involuntary eye movement)
- Seizures in some cases
- Speech difficulties
As the disease progresses, individuals may experience further neurological deterioration, although the rate of progression can vary widely among affected individuals.
Causes[edit | edit source]
Salla disease is caused by mutations in the SLC17A5 gene, which encodes a protein involved in the transport of sialic acid out of lysosomes. Mutations in this gene lead to the accumulation of sialic acid within lysosomes, disrupting normal cellular function and leading to the symptoms of the disease.
Diagnosis[edit | edit source]
Diagnosis of Salla disease involves a combination of clinical evaluation, biochemical tests to measure the levels of free sialic acid in urine, and genetic testing to identify mutations in the SLC17A5 gene.
Treatment[edit | edit source]
There is currently no cure for Salla disease. Treatment is symptomatic and supportive, focusing on managing symptoms and improving quality of life. This may include physical therapy, speech therapy, and medications to manage seizures and other symptoms.
Epidemiology[edit | edit source]
Salla disease is most common in individuals of Finnish descent, particularly those from the Salla region, but it has been identified in various ethnic groups worldwide. The exact prevalence is unknown, but it is considered a rare disease.
Research[edit | edit source]
Research into Salla disease is focused on understanding the underlying mechanisms of the disease and developing effective treatments. Gene therapy and enzyme replacement therapy are areas of interest, but these approaches are still in the experimental stages.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD